Understanding Thalassemia: An Inherited Blood Disorder

Millions of people around the world are born with a condition that quietly affects one of the most vital functions of the human body – the ability to carry oxygen in the blood. Thalassemia is one such condition, and while it may not always make headlines, it is one of the most common inherited disorders on the planet. Understanding what thalassemia is, how it works, and how widespread it is forms the foundation of recognizing it as a serious global health concern that demands attention, awareness, and informed support.

What is thalassemia? 🔗

Thalassemia is an inherited blood disorder in which the body does not produce enough hemoglobin – the protein inside red blood cells responsible for carrying oxygen to every cell in the body. When hemoglobin levels are too low, red blood cells cannot function properly and have a shorter lifespan than normal, leading to fewer healthy red blood cells circulating in the bloodstream. This results in anemia, which can range from mild to life-threatening depending on the form of the disorder.

The condition is genetic, meaning it is passed from parents to children through faulty or missing genes. At least one parent must be a carrier for the disorder to be transmitted to the next generation. Hemoglobin molecules are made up of protein chains called alpha and beta chains, and thalassemia disrupts the production of one or both of these chains. Depending on which chain is affected, the condition is classified as either alpha-thalassemia or beta-thalassemia.

The role of hemoglobin in the body 🔗

To understand thalassemia, it helps to understand what hemoglobin does. Every red blood cell is packed with hemoglobin, a protein that picks up oxygen in the lungs and delivers it to tissues and organs throughout the body. When thalassemia is present, the disorder results in large numbers of red blood cells being destroyed, which reduces the oxygen-carrying capacity of the blood. Oxygen is essential for cells to function – without enough of it, a person may feel tired, weak, and breathless. In severe cases, vital organs are deprived of oxygen, leading to serious complications.

The two main types of thalassemia 🔗

Thalassemia is not a single condition but a group of related disorders with varying degrees of severity. The two primary types – alpha and beta – refer to which part of the hemoglobin molecule is affected.

Alpha-thalassemia 🔗

Alpha-thalassemia occurs when one or more of the four alpha-globin genes that make up part of the hemoglobin molecule are missing or damaged. The severity of the condition depends entirely on how many of these genes are affected. When only one gene is missing, a person is a silent carrier with no noticeable symptoms. When two genes are missing, mild anemia may develop. When three genes are missing, the resulting condition – known as hemoglobin H disease – causes moderate to severe anemia. When all four genes are absent, the condition is almost always fatal before or shortly after birth.

Beta-thalassemia 🔗

Beta-thalassemia involves the two genes responsible for producing the beta-globin chain of hemoglobin. If one of these genes is altered, a person becomes a carrier with mild or no symptoms – a condition called beta-thalassemia minor or trait. If both genes are altered, the person develops beta-thalassemia intermedia or beta-thalassemia major, also known as Cooley’s anemia. In the most severe form, babies appear healthy at birth but begin developing serious anemia within the first two years of life, requiring lifelong medical management.

Recognizing the symptoms 🔗

The symptoms of thalassemia vary widely based on the type and number of faulty genes inherited. Mild forms may produce no symptoms at all, while severe forms present a range of noticeable health challenges. In infants with beta-thalassemia and some types of alpha-thalassemia, symptoms usually appear after the age of six months, once fetal hemoglobin is gradually replaced by the adult form and the genetic defect becomes apparent.

Common symptoms in moderate to severe thalassemia include persistent fatigue and weakness, pale or yellowish skin (jaundice), an enlarged spleen or liver, slow growth and delayed development in children, bone problems – particularly in the face and skull – and a higher susceptibility to infections. In beta-thalassemia major, severe anemia develops and is associated with fatigue, weakness, shortness of breath, dizziness, headaches, and yellowing of the skin and whites of the eyes. Many people with the thalassemia trait, however, may go through life without ever realizing they carry the altered gene.

How thalassemia is diagnosed 🔗

Diagnosis is typically confirmed through blood tests, though the pathway varies depending on whether the disorder is suspected in a newborn, a child already showing symptoms, or an adult who may be a carrier. Blood tests that help confirm the diagnosis include a complete blood count (CBC), hemolysis tests, iron blood tests, hemoglobin analysis, and genetic testing to detect abnormal genes.

For families at high risk – where both parents are known carriers – prenatal diagnosis using chorionic villus sampling at 8 to 10 weeks or by amniocentesis at 14 to 20 weeks of gestation is an option. This allows parents to understand the likelihood of passing the condition on to their child and make informed decisions accordingly. Genetic counseling plays an important role at this stage, helping families navigate the implications of carrier status and inherited risk.

Managing thalassemia: a lifelong commitment 🔗

There is currently no universal cure for thalassemia, and for those with moderate to severe forms, management is an ongoing, lifelong process. The treatment approach depends entirely on the type and severity of the condition.

Blood transfusions 🔗

Blood transfusions are the main way to treat moderate or severe thalassemia, replenishing healthy red blood cells that the patient’s body cannot produce adequately. People with thalassemia major typically require between eight and twelve transfusions a year. While transfusions are effective, they come with a significant side effect: iron overload. Because red blood cells carry large amounts of iron, repeated transfusions cause iron to accumulate in the organs – particularly the heart and liver – and can cause serious damage if not managed.

Iron chelation therapy 🔗

To counteract iron overload, patients on regular transfusion programs require iron chelation therapy – a treatment in which medication binds to excess iron and removes it from the body through urine or stools. Doctors may prescribe deferoxamine, given by injection, or deferasirox, which is taken orally. Chelation therapy is typically started within one to two years of beginning regular transfusions and must be maintained consistently to protect organ function.

Stem cell transplant and gene therapy 🔗

For eligible patients – typically younger children with a suitable matched donor – a stem cell (bone marrow) transplant offers the possibility of a lasting cure. For children with severe thalassemia, it can eliminate the need for lifelong blood transfusions and drugs to control iron overload. More recently, gene therapy has emerged as a promising frontier. In January 2024, the U.S. Food and Drug Administration approved CASGEVY™, a cell-based gene therapy for the treatment of transfusion-dependent beta-thalassemia in patients aged 12 years and older. This marks a significant advance in treatment options for those who previously had limited alternatives to lifelong transfusions.

Lifestyle and supportive care 🔗

Beyond medical treatments, people living with thalassemia benefit from careful attention to lifestyle. This includes maintaining a balanced diet, avoiding foods high in iron unless medically advised otherwise, staying up to date on vaccinations – especially important for those who receive transfusions – taking folic acid supplements to support red blood cell production, and engaging in regular, appropriate physical activity. Avoiding tobacco and excess alcohol helps protect bone and heart health, both of which can be compromised by severe forms of the disorder.

The global reach of thalassemia 🔗

The name “thalassemia” comes from the Greek word thalassa, meaning “the sea,” a reference to its original identification in communities around the Mediterranean Sea. The condition was first described in populations living near the Mediterranean Sea; however, the disease is also prevalent in Africa, the Middle East, and Asia. Today, it is recognized by the World Health Organization as a major global health concern, with a distribution that spans continents and affects millions.

The 2021 Global Burden of Disease Survey found that 1.31 million people worldwide have severe thalassemia, while the thalassemia trait occurs in 358 million people, causing around 11,100 deaths annually. The scale of this figure underscores why thalassemia cannot be treated as a regional issue – it is, unmistakably, a global one.

Geographic hotspots 🔗

While thalassemia occurs across the world, certain regions bear a disproportionately high burden. Beta-thalassemia carriers account for approximately 3% of the global population, with the Africa, Mediterranean basin, Middle East, Indian subcontinent, Southeast Asia, Melanesia, and the Pacific Islands among the most affected areas. Carrier frequency in these regions can range from 1% to as high as 20% for beta-thalassemia alone.

In the Mediterranean, countries such as Greece, Italy, Cyprus, and Turkey have historically recorded the highest rates. Thalassemia prevalence is highest in the Mediterranean, the Middle East, and Southeast Asia. In South Asia, the picture is equally significant – India alone has over 42 million carriers and sees between 10,000 and 12,000 infants born with thalassemia each year, contributing around 10% of all thalassemia major births worldwide.

Why these regions are most affected 🔗

The geographic concentration of thalassemia is not coincidental. Thalassemia is more common in people with ancestral links to parts of the world with malaria – including Africa, Southern Europe, and West, South, and East Asia – because the genes that cause thalassemia arose in humans to help protect against malaria. Carriers of thalassemia trait have a degree of natural resistance to malaria, which meant that over generations, the altered genes spread and remained prevalent in malaria-endemic populations. This evolutionary dynamic explains why the disorder is so deeply embedded in specific geographic and ancestral communities.

A shifting global distribution 🔗

Thalassemia is no longer confined to its traditional geographic hotspots. Due to migration patterns, beta-thalassemia is increasingly more common in non-endemic regions, including Western Europe and North America. As populations move across borders for economic, social, or personal reasons, they carry their genetic heritage with them, introducing thalassemia into healthcare systems that may have little experience with the condition. This shift makes international awareness, cross-border medical cooperation, and culturally sensitive screening programs more important than ever.

Encouragingly, prevention efforts are making a measurable difference in high-prevalence countries. Mandatory premarital screening programs – such as those introduced in Saudi Arabia in 2004 – have shown a significant reduction in new thalassemia cases. Prenatal screening, genetic counseling, and improved access to diagnostic services are collectively helping to reduce the number of children born with severe thalassemia in regions where resources allow for such programs.

What do you think? Given that thalassemia affects hundreds of millions of people globally and its distribution is shifting due to migration, how prepared do you think healthcare systems in traditionally low-prevalence countries are to support patients with this condition? And for communities where thalassemia is deeply common, what role should schools and educators play in raising awareness about genetic carrier status among young people?

References

1. https://www.cdc.gov/thalassemia/about/index.html
2. https://www.mayoclinic.org/diseases-conditions/thalassemia/symptoms-causes/syc-20354995
3. https://medlineplus.gov/ency/article/000587.htm
4. https://www.hopkinsmedicine.org/health/conditions-and-diseases/alpha-thalassemia
5. https://www.nhlbi.nih.gov/health/thalassemia/causes
6. https://www.medicalnewstoday.com/articles/263489
7. https://rarediseases.org/rare-diseases/thalassemia-major/
8. https://my.clevelandclinic.org/health/diseases/14508-thalassemias
9. https://www.ncbi.nlm.nih.gov/books/NBK545151/
10. https://www.cdc.gov/thalassemia/treatment/index.html
11. https://www.mayoclinic.org/diseases-conditions/thalassemia/diagnosis-treatment/drc-20355001
12. https://ada.com/conditions/thalassemia/
13. https://www.ncbi.nlm.nih.gov/books/NBK22200/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11090906/
15. https://en.wikipedia.org/wiki/Thalassemia
16. https://www.sciencedirect.com/science/article/abs/pii/S0378111923008636
17. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00198-6/fulltext
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC7692954/